<--- Back to Details
First PageDocument Content
Food and Drug Administration / Clinical research / Pharmaceutical industry / Validation / Cord blood / Gene therapy / Center for Biologics Evaluation and Research / Current Good Tissue Practices / Biology / Biotechnology / Stem cells
Date: 2008-03-27 11:33:16
Food and Drug Administration
Clinical research
Pharmaceutical industry
Validation
Cord blood
Gene therapy
Center for Biologics Evaluation and Research
Current Good Tissue Practices
Biology
Biotechnology
Stem cells

Update on OCTGT Guidance Development Program

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 40,37 KB

Share Document on Facebook

Similar Documents

Large ElectronPositron Collider

Biotechnology, BS "DBEFNJD.BQ  5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT

DocID: 1xTqy - View Document

PDF Document

DocID: 1wroO - View Document

Building A Better Mousetrap: Patenting Biotechnology In The European Community

DocID: 1vr7C - View Document

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

DocID: 1vq6b - View Document

Biotechnology Consultation Agency Response Letter BNF

DocID: 1vpUZ - View Document